Cagrilintide
Cagrilintide (AM833, NNC0174-0833)
Long-acting synthetic amylin analogue for weight management and type 2 diabetes. Works as a dual amylin and calcitonin receptor agonist (DACRA), mimicking natural amylin hormone to regulate appetite, slow gastric emptying, and promote satiety.
Cagrilintide Dosing Guide
Primary Benefits
- Significant weight loss (up to 20.4% with CagriSema)
- Appetite suppression and satiety enhancement
- Improved glycemic control in diabetes
- Reduced food cravings and portion sizes
- Enhanced weight loss when combined with semaglutide
How It Works
Cagrilintide works through specific biological pathways to deliver therapeutic benefits.
What It's Used For
Long-acting synthetic amylin analogue for weight management and type 2 diabetes. Works as a dual amylin and calcitonin receptor agonist (DACRA), mimicking natural amylin hormone to regulate appetite, slow gastric emptying, and promote satiety.
Weight Management
Advanced appetite suppression through amylin pathway activation for significant weight loss
Combination Therapy
Works synergistically with semaglutide in CagriSema for enhanced weight loss results
Metabolic Health
Improves glucose tolerance and insulin sensitivity for better metabolic function
How Much to Take
Dose Escalation Protocol
CagriSema Combination
Advanced Protocol
Combined with semaglutide for enhanced weight loss (15-25% reduction)
Dual Pathway Action
Works on both amylin and GLP-1 pathways for superior appetite control
Frequency
Once weekly injection
Timing
Same day each week
Adjustment
Based on tolerance
How Long to Use It
Cagrilintide is designed for long-term weight management with sustained appetite suppression. Clinical trials have studied treatment periods of 26-68 weeks with continued effectiveness. The medication requires ongoing use to maintain weight loss benefits, as discontinuation typically leads to weight regain.
Important Research Status
Cagrilintide is currently in Phase 3 clinical trials and is not yet commercially available. Access may be limited to clinical trial participation through research centers.
Need-to-Know Information
How It Works
Key Benefits
Who Should Avoid
- Personal or family history of medullary thyroid carcinoma
- Multiple Endocrine Neoplasia syndrome type 2
- Known hypersensitivity to cagrilintide
- Severe gastroparesis
Common Side Effects
- Nausea (20-47%)
- Constipation
- Vomiting
- Abdominal pain
Storage & Injection
Storage Requirements
Refrigerate unopened vials at 2-8°C (36-46°F). Do not freeze. Protect from light. Once in use, can be stored at room temperature up to 30°C for 4 weeks.
Shelf Life
7-day half-life allows flexible weekly dosing. Can be stored at room temperature for up to 4 weeks once in use.
Injection Sites
Abdomen, thigh, upper arm
Method
Subcutaneous injection
Rotation
Weekly site rotation
Example Schedule
16-Week Dose Escalation Protocol
Month 1
0.3 mg weekly
Month 2
0.6 mg weekly
Month 3
1.2 mg weekly
Month 4+
2.4 mg weekly
Missed Dose Protocol
If you miss your weekly injection, take it as soon as possible within 3 days. If more than 3 days have passed, skip the missed dose and continue with your regular schedule. Never double dose.
Extra Tips for Best Results
Lifestyle Support
Combine with reduced-calorie diet and regular exercise for optimal weight loss results
Monitor Progress
Track weight, measurements, and side effects weekly during dose escalation
Medical Support
Work closely with healthcare provider for dose adjustments and side effect management
Side Effect Management
Eat smaller meals, stay hydrated, and increase fiber intake to minimize GI side effects
Expected Results Timeline
Clinical trials show 8-15% weight loss with monotherapy over 26 weeks, and 15-25% weight loss with CagriSema combination therapy. Maximum benefits typically seen after reaching maintenance dose at week 16.
Research Phase Medication
Cagrilintide is currently in Phase 3 clinical trials and requires medical supervision. Access is typically limited to clinical trial participation or specialized research centers.
Medical Disclaimer
Clinical data presented is from peer-reviewed studies. Individual results may vary. Consult healthcare professionals before starting treatment. This information is for educational purposes only.